Search results for "Pathologic"

showing 10 items of 710 documents

Adjuvant chemotherapy for early-stage breast cancer patients — daily clinical practice in selected cancer centres in Poland

2017

Background. Adjuvant chemotherapy for high-risk early-stage breast cancer patients significantly improves long-term treatment results. The decision to administer chemotherapy is made based primarily on prognostic factors (defined by the pathological characteristics of the primary tumour and regional lymph nodes) and also on patient-related factors, such as age, menopausal status and comorbidities. The guidelines on adjuvant chemotherapy have been established and reviewed for many years by several medical societies (NCCN, ESMO, PTOK, PUO) and experts of St. Gallen International Breast Cancer Conference. The aim of this study was to assess the pattern of adjuvant chemotherapy administration t…

OncologyCancer Researchmedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentCancermedicine.diseaseBreast cancerOncologyTrastuzumabInternal medicinemedicineStage (cooking)businessAdjuvantPathologicalmedicine.drugNowotwory. Journal of Oncology
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and patho…

2018

Background The molecular classification of gastric cancer recognises two subtypes prone to immune checkpoint blockade: the microsatellite unstable and the Epstein-Barr virus (EBV)-related tumours. We aim to assess the concordance between immunohistochemistry and PCR for microsatellite status evaluation, and explore the value of microsatellite instability (MSI) and EBV as predictive survival factors. Material and methods We collected 246 consecutively diagnosed gastric cancer cases in all stages and evaluated the microsatellite status using immunohistochemistry for mismatched repair (MMR) proteins and PCR. EBV expression was studied through in situ hybridisation. Results Forty-five (18%) cas…

OncologyCancer Researchmedicine.medical_specialtyConcordancemedicine.disease_causelcsh:RC254-282Internal medicinemedicine1506PathologicalOriginal Researchepstein-barr virusbusiness.industrygastric cancerCancerMicrosatellite instabilitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseEpstein–Barr virusImmune checkpointdigestive system diseasesOncologyImmunohistochemistryMicrosatellitemicrosatellite instabilitybusinessESMO open
researchProduct

Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance

2021

Regular colonoscopy even with short intervals does not prevent all colorectal cancers (CRC) in Lynch syndrome (LS). In the present study, we asked whether cancers detected under regular colonoscopy surveillance (incident cancers) are phenotypically different from cancers detected at first colonoscopy (prevalent cancers). We analyzed clinical, histological, immunological and mutational characteristics, including panel sequencing and high-throughput coding microsatellite (cMS) analysis, in 28 incident and 67 prevalent LS CRCs (n total = 95). Incident cancers presented with lower UICC and T stage compared to prevalent cancers (p &lt

OncologyColorectal cancerColonoscopybiomarkkeritHEREDITARYGUIDELINESTp53 mutationmedicine.disease_causeMolecular level0302 clinical medicineRISKincident cancercancer preventionmedicine.diagnostic_testRGeneral MedicineTUMORSLynch syndrome3. Good healthsyöpäsolutCARCINOMAS030220 oncology & carcinogenesisMedicineDNA mismatch repair030211 gastroenterology & hepatologyKRAScarcinogenesiskoloskopiamedicine.medical_specialtyDATABASEcolorectal cancersuolistosyövätmikrosatelliititArticle03 medical and health sciencescolonoscopy screeningInternal medicinemutational profilingmedicineLynchin oireyhtymäPathologicalpaksusuolisyöpäCancer preventionmismatch repair deficiencybusiness.industryMicrosatellite instabilitySCREENING INTERVAL3126 Surgery anesthesiology intensive care radiologymedicine.diseasedigestive system diseasesMSH2Lynch syndromeMSH23121 General medicine internal medicine and other clinical medicineT-stageCLINICAL MANAGEMENTmicrosatellite instabilitymutaatiotbusinessJournal of Clinical Medicine
researchProduct

Squamous Cell Carcinoma: Clinical and Pathological Features and Associated Risk Factors in an Observational Study of 118 Patients

2015

Background and objective: In the latest edition of its cancer staging manual, the American JointCommittee on Cancer (AJCC) revised the criteria for staging squamous cell carcinoma (SCC) by introducing high-risk tumor features to define tumor stage (T) and help to identify tumors with a higher risk of metastasis. The aim of this study was to investigate the characteristics associated with SCC meeting the high-risk criteria defined by the AJCC for T2 lesions. Patients and method: We performed a case-case observational study in which patients with SCC were included over a period of 18 months. We collected clinical, anthropometric, and tumor data, and analyzed these using PASW Statistics (SPSS)…

OncologyMalemedicine.medical_specialtyHistologyNeoplasms Radiation-InducedSkin NeoplasmsCumulative ExposureSkin PigmentationDermatologyComorbidityPathology and Forensic MedicineMetastasisRisk FactorsInternal medicinemedicineHumansPathologicalCancer stagingAgedNeoplasm StagingGynecologyAged 80 and overAnthropometrybusiness.industrySmokingAge FactorsCancerOdds ratiomedicine.diseaseComorbidityTumor BurdenKeratosis ActinicHead and Neck NeoplasmsSpainCarcinoma Squamous CellObservational studyFemalebusiness
researchProduct

Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAor=10 ng/ml?

2005

<i>Introduction:</i> To evaluate whether percent free prostate-specific antigen (%-fPSA) could be predictive of pathological stage and Gleason score in patients with prostate cancer (PCa) and serum PSA of 10 ng/ml or less. <i>Materials and Methods:</i> In 100 patients with total PSA≤10 ng/ml who underwent radical retropubic prostatectomy as primary treatment of PCa, %-fPSA levels in organ-confined vs. non-organ-confined PCa and in patients with Gleason score ≤/>7 were compared. <i>Results:</i> 32 patients had an organ-confined and 68 a locally advanced PCa. Median %-fPSA level was 15%; Gleasonscore was <7 in 49 patients, equal to 7 in 40 and >7 i…

OncologyMalemedicine.medical_specialtybusiness.industryUrologyUrologyProstatic NeoplasmsMiddle AgedProstate-Specific Antigenurologic and male genital diseasesmedicine.diseaseProstate cancerAntigenInternal medicinemedicineHumansNeoplasm stagingIn patientProstate cancer stagingStage (cooking)businessPathologicalTotal psaAgedNeoplasm StagingUrologia internationalis
researchProduct

An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.

2019

Introduction: The angiogenesis mechanism is considered a crucial point in neoplastic development. A growing number of multi-targeted tyrosine kinase inhibitors (TKI) has been developed and approved for cancer treatment during the last few years. Cardiac side effects still remain an issue to manage nowadays. These drugs mechanisms and toxicities have already been discussed, hence the authors will report updates on these already available drugs. Area covered: This manuscript provides an updated review on the new mechanisms involved in angiogenesis and cardiotoxicity that are TKI-related. Here is reported an overview of the already available and the most recent TKIs under investigation in the …

OncologyTumor angiogenesismedicine.medical_specialtyAngiogenesisupdateVEGFR-TKIAngiogenesis InhibitorsAntineoplastic Agents030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsmedicineAnimalsHumansPharmacology (medical)Cardio oncologyCooperative BehaviorCrucial pointProtein Kinase InhibitorsNeovascularization Pathologicbusiness.industrycardiovasculartoxicityGeneral MedicineCardiotoxicityrespiratory tract diseasesReceptors Vascular Endothelial Growth Factor030220 oncology & carcinogenesisoncologybusinessTyrosine kinasemanagementExpert opinion on drug safety
researchProduct

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Oncologymedicine.medical_specialtyPathologyStagingPET/CTmedicine.medical_treatmentBiophysicsEstrogen receptorER-positive breast cancerNeoadjuvant chemotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerTriple-negative breast cancerResponse assessmentInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineRadiology Nuclear Medicine and imagingskin and connective tissue diseasesHER2-positive breast cancerTriple-negative breast cancerChemotherapyPET-CTPathological complete responseRadiological and Ultrasound Technologybusiness.industrymedicine.disease18fdg pet ctPrognosis3. Good healthHormone receptor030220 oncology & carcinogenesisInvasive lobular carcinoma(18)FDGbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Prognostic comparison of the pathological classifications of gastric cancer: a population-based study

1998

Aims There is controversy over the value of the pathological classifications of gastric carcinomas in the prediction of patient survival. This study was designed to assess the prognostic value of four widely used pathological classifications, in addition to classical prognostic factors. Methods and results Records from the population-based registry of digestive tract tumours in the department of Cote d'Or (France) have been analysed. All available histopathological slides of gastric cancer resected between 1976 and 1985 were reviewed and classified according to World Health Organization (WHO), Lauren, Ming and Goseki pathological coding systems. A relative survival analysis was performed us…

Oncologymedicine.medical_specialtyPathologyeducation.field_of_studyHistologyMultivariate analysisRelative survivalbusiness.industryStomachPopulationCancerGeneral Medicinemedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureInternal medicinemedicineAdenocarcinomaeducationbusinessPathologicalSurvival rateHistopathology
researchProduct

18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer

2016

International audience; Previous studies have suggested that early changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with 150-water are a surrogate biomarker of outcome in women with breast cancer. This study investigates, in the triple-negative breast cancer subtype, the prognostic relevance of tumor BF changes (Delta BF) in response to chemotherapy, assessed using a short dynamic F-18-FDG PET acquisition. Methods: Forty-six consecutive women with triple-negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included. Women benefited from a baseline F-18-FDG PET examination with a 2-min chest-centered dynamic acquisition, sta…

Oncologymedicine.medical_specialtyPrognostic-FactorsBevacizumabSurvival[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineperfusion[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineblood flowRadiology Nuclear Medicine and imaging[ SDV.IB ] Life Sciences [q-bio]/BioengineeringTomography[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingNeoadjuvant therapyTriple-negative breast cancerSubtypesMarkersChemotherapytriple-negativemedicine.diagnostic_testbusiness.industryTriple Negative Breast Neoplasmsmedicine.disease3. Good healthBevacizumabPETMetabolismPositron emission tomography030220 oncology & carcinogenesisBiomarker (medicine)Pathological Response[SDV.IB]Life Sciences [q-bio]/BioengineeringAngiogenesisTherapybusinessmedicine.drug
researchProduct